Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016

  • ID: 3802756
  • Report
  • 120 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Immunomedics, Inc.
  • Merck & Co., Inc.
  • MORE
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016

Summary

‘Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Review, H1 2016’, provides in depth analysis on Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
- The report reviews Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Immunomedics, Inc.
  • Merck & Co., Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Overview

Therapeutics Development

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Stage of Development

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Therapy Area

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Indication

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Companies

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Products under Development by Universities/Institutes

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Amgen Inc.

Antisense Therapeutics Limited

Astellas Pharma Inc.

AstraZeneca Plc

Axelar AB

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Genmab A/S

Immunomedics, Inc.

Insmed Incorporated

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

Novartis AG

PharmAbcine, Inc.

ProteoThera, Inc.

Silver Creek Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc.

TyrNovo Ltd.

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drug Profiles

1R-15-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

1R-3s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

1R-E1-E1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATL-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AXL-1717 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-3463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-893923 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-754807 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-707 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalotuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganitumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenaldekar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linsitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-590 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mecasermin rinfabate (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MM-141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-219 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize Insulin Like Growth Factor 1 Receptor for Phelan-McDermid Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RU-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize IGF-1R for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IGF-1R for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IGF-1R/IR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teprotumumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HER-2, IGFBP-2 and IGF1R for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vesiculin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XGFR-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XGFR-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Dormant Projects

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Discontinued Products

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Featured News & Press Releases

Jul 29, 2015: CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave’s Orbitopathy

May 05, 2015: Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer

Apr 21, 2015: First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients

Mar 17, 2015: Study suggests precision medicine for adrenal cancer

Jan 20, 2015: Merrimack Pharmaceuticals Presents First-in-human study of MM-141 at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium

Nov 05, 2014: FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals MM-141 for the Treatment of Pancreatic Cancer

Jun 02, 2014: Merrimack Pharmaceuticals Presents Phase 1 Clinical Data From MM-141 at the 2014 ASCO Annual Meeting

Feb 18, 2014: Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics

Jan 14, 2014: AmorChem Invests In A Potential Therapy For Late-Stage Breast Cancer

Dec 27, 2013: Axelar announces final data from Phase II study with AXL1717 in lung cancer

Oct 15, 2013: Merrimack Pharmaceuticals to Present Preclinical Data On MM-141 at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease

Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy

Apr 02, 2013: Axelar Announces Preliminary Results From Phase II Study Demonstrating Efficacy Of AXL1717 In Non-Small Cell Lung Cancer Patients

Jan 21, 2013: Axelar Initiates Phase I/II Study Of AXL1717 In Patients With Malignant Astrocytomas In US

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 120List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by Antisense Therapeutics Limited, H1 2016

Pipeline by Astellas Pharma Inc., H1 2016

Pipeline by AstraZeneca Plc, H1 2016

Pipeline by Axelar AB, H1 2016

Pipeline by Boehringer Ingelheim GmbH, H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Eli Lilly and Company, H1 2016

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pipeline by Genmab A/S, H1 2016

Pipeline by Immunomedics, Inc., H1 2016

Pipeline by Insmed Incorporated, H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by PharmAbcine, Inc., H1 2016

Pipeline by ProteoThera, Inc., H1 2016

Pipeline by Silver Creek Pharmaceuticals, Inc., H1 2016

Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016

Pipeline by TyrNovo Ltd., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Dormant Projects (Contd..3), H1 2016

Dormant Projects (Contd..4), H1 2016

Dormant Projects (Contd..5), H1 2016

Dormant Projects (Contd..6), H1 2016

Discontinued Products, H1 2016

Discontinued Products (Contd..1), H1 2016

Discontinued Products (Contd..2), H1 2016

Discontinued Products (Contd..3), H1 2016

Discontinued Products (Contd..4), H1 2016 107List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Immunomedics, Inc.
  • Merck & Co., Inc.
  • MORE
Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) pipeline Target constitutes close to 34 molecules. Out of which approximately 24 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Insulin Like Growth Factor 1 Receptor - Pipeline Review, H1 2016, outlays comprehensive information on the Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Insulin-like growth factor 1 (IGF-1) receptor is a transmembrane receptor found on human cells. IGF1 bind to it with high affinity and IGF2 and insulin (INS) with a lower affinity. Ligand binding leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. The activated IGF1R is involved in cell growth and survival control by two main signaling pathways PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. JNK kinases is also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 9, 11 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 3 molecules, respectively.

Furthermore, this report also reviews key players involved in Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Amgen Inc.
Antisense Therapeutics Limited
Astellas Pharma Inc.
AstraZeneca Plc
Axelar AB
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genmab A/S
Immunomedics, Inc.
Insmed Incorporated
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
Novartis AG
PharmAbcine, Inc.
ProteoThera, Inc.
Silver Creek Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
TyrNovo Ltd.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll